Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib

Biomarkers of PARP inhibitor sensitivity

(2011) Nicholas C. Turner et al.   BREAST CANCER RESEARCH AND TREATMENT

MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers

(2011) E. Vilar et al.   CANCER RESEARCH

Genetic Interactions in Cancer Progression and Treatment

(2011) Alan Ashworth et al.   CELL

A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer

(2011) Christos Hatzis   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

PARP inhibitors stumble in breast cancer

(2011) Malini Guha   NATURE BIOTECHNOLOGY

Germline mutations in RAD51D confer susceptibility to ovarian cancer

(2011) Chey Loveday et al.   NATURE GENETICS

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

(2011) B Weigelt et al.   ONCOGENE

Subtype and pathway specific responses to anticancer compounds in breast cancer

(2011) L. M. Heiser et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations

(2010) Henne Holstege et al.   BMC CANCER

DNA repair signature is associated with anthracycline response in triple negative breast cancer patients

(2010) A. A. Rodriguez et al.   BREAST CANCER RESEARCH AND TREATMENT

Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis

(2010) Anthony Gonçalves et al.   BREAST CANCER RESEARCH AND TREATMENT

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

(2010) M. Graeser et al.   CLINICAL CANCER RESEARCH

Mre11–Rad50–Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks

(2010) Gareth J. Williams et al.   DNA REPAIR

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy

(2010) S. Moulder et al.   MOLECULAR CANCER THERAPEUTICS

ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors

(2010) C. T. Williamson et al.   MOLECULAR CANCER THERAPEUTICS

DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization

(2010) H. Christian Reinhardt et al.   MOLECULAR CELL

The DNA Damage Response: Making It Safe to Play with Knives

(2010) Alberto Ciccia et al.   MOLECULAR CELL

Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination

(2010) Rémi Buisson et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Immunophenotypic predictive profiling of BRCA1-associated breast cancer

(2010) Pawel Domagala et al.   VIRCHOWS ARCHIV

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

(2009) T Zaremba et al.   BRITISH JOURNAL OF CANCER

Family History, Genetic Testing, and Clinical Risk Prediction: Pooled Analysis of CHEK2*1100delC in 1,828 Bilateral Breast Cancers and 7,030 Controls

(2009) O. Fletcher et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors

(2009) Ana M. Mendes-Pereira et al.   EMBO Molecular Medicine

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synthetic Lethality — A New Direction in Cancer-Drug Development

(2009) J. Dirk Iglehart et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Mutant Allele of MRE11 Found in Mismatch Repair-deficient Tumor Cells Suppresses the Cellular Response to DNA Replication Fork Stress in a Dominant Negative Manner

(2008) Qin Wen et al.   MOLECULAR BIOLOGY OF THE CELL

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE